Media.Player

A-10 GABAB Agonist: A Novel Therapeutic Agent for Diabetes & Obesity

技術優勢

ΓùÅ Treats only excessive adipose stores in obese subjects.ΓùÅ Increase sensitivity to insulin for Type II diabetic patients

技術應用

ΓùÅTherapeutic reagents for obesityΓùÅ Animal drug for obesity

詳細技術說明

Researchers examined baclofen with animal models and obese patients including seven women and three men ranging from 25-51 years of age. Baclofen significantly decreased food intake and body weight in obese animals such as db/db mice and diet-induced obesity (DIO) mice, followed by decreased levels of blood glucose and insulin. The effects of baclofen on food intake and body weight were unique in that it had significant effects only in obese mice but not in lean control. Baclofen also decreased both body weight and waist circumference in obese patients. Serum leptin levels, which possibly reflect the amount of adipose stores, were decreased significantly by the treatment. The decreases in body weight were accompanied by reduced concentration of blood glucose and Insulin after 12 week administration, although the differences did not reach statistical significance. On the other hand, there were no significant changes in the blood pressure or lipid metabolism. No adverse effects were observed. These results indicate that baclofen decreases body weight in obese subjects and possibly increases insulin sensitivity in type 2 diabetes patients.

*Abstract

Baclofen, a GABAB agonist, has been used to treat muscle stiffness in patients with multiple sclerosis or cerebral palsy without apparent side effects.

附加資料

Patent Number: US8906422B2
Application Number: US2007871068A
Inventor: Kwong, Yok-Lam
Priority Date: 9 Oct 2002
Priority Number: US8906422B2
Application Date: 11 Oct 2007
Publication Date: 9 Dec 2014
IPC Current: A61K003336 | A61P003500
US Class: 424623
Assignee Applicant: The University of Hong Kong
Title: Method for inhibiting cancer using arsenic trioxide
Usefulness: Method for inhibiting cancer using arsenic trioxide
Summary: Composition (A) is useful for the treatment of hematological malignancies (preferably acute myeloid leukemia (preferred), acute nonlymphocytic leukemia, myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythroleukemia, myelodysplastic syndrome, acute promyelocytic leukemia (preferred), chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, polycythemia vera, Hodgkin's lymphoma, non-Hodgkin's lymphomas, myeloma, giant cell myeloma, indolent myeloma, localized myeloma, multiple myeloma, plasma cell myeloma, sclerosing myeloma, solitary myeloma, smoldering multiple myeloma, nonsecretary myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma). (all claimed)

主要類別

診斷/治療

細分類別

其他疾病

國家/地區

美國